<DOC>
	<DOCNO>NCT01978977</DOCNO>
	<brief_summary>Investigators propose ass , safety tolerability profile ( number participant adverse event ) bevacizumab ( Avastin ) combine standard chemotherapy first line treatment patient metastatic Breast Cancer .</brief_summary>
	<brief_title>Maintenance Bevacizumab Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer</brief_title>
	<detailed_description>Nowadays clinical practice patient previously untreated metastatic breast cancer often receive taxane-based chemotherapy ( paclitaxel docetaxel ) combination bevacizumab show increase progression-free survival . There currently minimal information whether bevacizumab give maintenance therapy discontinuation chemotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Written inform consent Age ≥18 year Patients histologically cytologically confirm , HER2negative , metastatic Breast Cancer No prior first line treatment metastatic Breast Cancer Previous hormonotherapy metastatic Breast Cancer allow One measurable lesion ( ≥1cm diameter spiral CT scan ≥2cm conventional technique ) accord RECIST criterion ECOG performance status ≤2 Adequate haematological , renal hepatic function Urine protein &lt; 2+ ( dipstick ) Life expectancy ≥12 week Previous first line treatment metastatic colorectal cancer ( progression &gt; 12 month end adjuvant treatment ) Previous radiotherapy target lesion Patients brain metastasis and/or cancerous meningitis Presence history neoplasm except properly treat basal cell skin cancer situ cervical carcinoma Patients participate interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>mBC</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Anti-angiogenic agent</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>1st Line</keyword>
</DOC>